Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Swedencare AB (publ) (SECARE.ST)
Malmö, SE
Swedencare AB (publ), an enterprise established in 1993 and headquartered in Malmö, Sweden, operates with its subsidiaries to develop, produce, market, and sell a wide array of healthcare products, predominantly for animals. The company's flagship offering is the ProDen PlaqueOff line, focused on dental hygiene for dogs and cats. This popular range includes a food supplement powder designed to reduce plaque and tartar buildup, along with various chewable formats such as dental bites, bones (including mini versions for smaller dogs), and soft chews suitable for both felines and canines. Beyond dental care, Swedencare provides an extensive selection of nutritional supplements under the NutriScience brand for cats, dogs, and horses. These products address diverse health requirements: Glucosamine and Stomax aid in the rejuvenation of joint cartilage, bones, muscles, ligaments, and sinews; ArthriAid supports joint function and mobility; KalmAid offers a calming effect for anxious dogs; while OmegaAid and RevitalAid are formulated to promote healthy skin and coats. Furthermore, the company manufactures specialized supplements for horses, including Gastrocare to alleviate gastric pain and enhance appetite; Equine Gold for overall vitality; a horse-specific ArthriAid to assist with cartilage formation; and AnxiKalm, aimed at soothing excitable horses. Interestingly, Swedencare also caters to human health with ProDen PlaqueOff Teeth and Gums, a natural dietary supplement designed to boost oral hygiene and prevent tartar accumulation. The company's products are distributed through a broad network that includes pharmacies, veterinary clinics, pet stores, animal hospitals, and online channels.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.80% | -0.36% | +1.49% | +8.76% | -27.49% | -29.37% | -32.43% | -38.75% | -74.29% | +658.33% | +658.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+6.1% Q1'26: +1.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-43.6% Q1'26: -26.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+9.7% Q1'26: +8.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+5.0% Q1'26: +8.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+1.1% Q1'26: +1.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.5% Q1'26: +0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.71× Q1'26: 3.39× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
85.66M
est: 87.70M (-2.3%)
|
99.14M
est: 97.60M (+1.6%)
|
126.87M
est: 129.62M (-2.1%)
|
239.95M
est: 233.05M (+3.0%)
|
770.44M
est: 764.44M (+0.8%)
|
1.83B
est: 1.87B (-1.9%)
|
2.34B
est: 2.47B (-5.4%)
|
2.54B
est: 2.57B (-1.1%)
|
2.69B
est: 2.70B (-0.3%)
|
2.89B
2.87B – 2.91B
+7.0% YoY
|
3.09B
3.03B – 3.13B
+6.8% YoY
|
3.35B
3.31B – 3.38B
+8.3% YoY
|
| EBITDA |
22.78M
est: 18.36M (+24.1%)
|
30.55M
est: 20.43M (+49.6%)
|
40.07M
est: 27.13M (+47.7%)
|
54.87M
est: 48.78M (+12.5%)
|
138.73M
est: 160.01M (-13.3%)
|
392.40M
est: 390.43M (+0.5%)
|
484.00M
est: 486.26M (-0.5%)
|
549.50M
est: 504.94M (+8.8%)
|
446.00M
est: 531.48M (-16.1%)
|
568.78M
565.35M – 573.16M
+7.0% YoY
|
607.45M
596.62M – 616.40M
+6.8% YoY
|
658.10M
651.69M – 664.50M
+8.3% YoY
|
| EBIT |
21.90M
est: 8.63M (+153.7%)
|
29.51M
est: 9.60M (+207.3%)
|
36.92M
est: 12.76M (+189.4%)
|
41.42M
est: 22.93M (+80.6%)
|
65.91M
est: 75.23M (-12.4%)
|
123.26M
est: 183.56M (-32.8%)
|
175.20M
est: 182.78M (-4.1%)
|
232.70M
est: 189.80M (+22.6%)
|
135.30M
est: 199.78M (-32.3%)
|
213.80M
212.51M – 215.44M
+7.0% YoY
|
228.33M
224.26M – 231.69M
+6.8% YoY
|
247.37M
244.96M – 249.78M
+8.3% YoY
|
| Net Income |
11.82M
est: 25.09M (-52.9%)
|
23.32M
est: 47.07M (-50.5%)
|
29.91M
est: 63.64M (-53.0%)
|
48.53M
est: 86.47M (-43.9%)
|
54.62M
est: 198.34M (-72.5%)
|
94.50M
est: 188.58M (-49.9%)
|
58.60M
est: 76.10M (-23.0%)
|
98.90M
est: 148.40M (-33.4%)
|
55.50M
est: 140.69M (-60.6%)
|
230.73M
201.25M – 260.20M
+64.0% YoY
|
275.04M
268.12M – 281.96M
+19.2% YoY
|
347.96M
326.57M – 369.34M
+26.5% YoY
|
| SGA |
18.48M
est: 12.60M (+46.6%)
|
20.54M
est: 14.02M (+46.5%)
|
25.19M
est: 18.62M (+35.3%)
|
43.62M
est: 33.48M (+30.3%)
|
149.85M
est: 109.82M (+36.4%)
|
625.67M
est: 267.96M (+133.5%)
|
—
est: 265.27M (-100.0%)
|
—
est: 275.47M (-100.0%)
|
—
est: 289.95M (-100.0%)
|
310.29M
308.42M – 312.68M
+7.0% YoY
|
331.39M
325.48M – 336.27M
+6.8% YoY
|
359.02M
355.52M – 362.51M
+8.3% YoY
|
| EPS |
0.22
est: 0.16 (+39.2%)
|
0.30
est: 0.30 (+1.2%)
|
0.38
est: 0.40 (-5.2%)
|
0.56
est: 0.54 (+2.8%)
|
0.49
est: 1.25 (-60.8%)
|
0.61
est: 1.19 (-48.6%)
|
0.37
est: 0.48 (-22.8%)
|
0.62
est: 0.93 (-33.4%)
|
0.35
est: 0.88 (-60.3%)
|
1.43
1.26 – 1.63
+62.5% YoY
|
1.73
1.68 – 1.77
+20.5% YoY
|
2.18
2.05 – 2.31
+26.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.02% | 133.0K | 0.40% |
| 2 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 19.8K | 0.30% |
| 3 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 599.1K | 0.03% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hakan Lagerberg | Chief Executive Officer | 7M | male |
| Edward Holden | Founder & Chief Executive Officer of Pet MD Brands LLC | — | male |
| Emma Nordgren | IR & Communications Manager | — | — |
| James Garcia | Chief Commercial Officer of Swedencare USA | — | — |
| Jenny Graflind | Chief Financial Officer | — | female |
| Laszlo Varga | Chief Commercial Officer of Europe | — | male |
| Martin Shimko | CEO & MD of Swedencare USA Inc. | — | male |
| Patrick Powell | Chief Operating Officer of Stratford Care & RX Vitamins Inc. | — | male |
| Renato della Valle | Co-Founder & Chief Executive Officer of Innovet Italia Srl | — | male |
| Sabine Uhde | Head of the Nordics-Swedencare Nordic AB | — | female |
| Simon Shaw | Head of Ecommerce Europe | — | male |
| Brian Nugent | Chief Commercial Officer of the North American Veterinary & Online Operations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SECARE.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
